Australia - English - Department of Health (Therapeutic Goods Administration)

stryker australia pty ltd - 44788 - spinal implant facsimile - manual medical tools designed solely for use in the fitting of stryker spine implants.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphatec australia pty ltd - 44788 - spinal implant facsimile - a copy of a final spinal prosthesis used to validate the proper size of the permanent implant required by the patient, to determine its appropriate position, and/or to verify that the implant site has been cut to the proper dimensions. this trial device is reusable.

Australia - English - Department of Health (Therapeutic Goods Administration)

acra regulatory services pty ltd - 44788 - spinal implant facsimile - copy of a spinal interbody fusion prosthesis, or other implantable device used to validate the proper size of the permanent implant required by the patient, to determine its appropriate position, and/or to verify that the implant site has been cut to the proper dimensions.

Australia - English - Department of Health (Therapeutic Goods Administration)

device technologies australia pty ltd - 44788 - spinal implant facsimile - a reusable device which is a copy of a final spinal device used to validate the proper size of the permanent implant required by the patient, to determine its appropriate position, and/or to verify that the implant site has been cut to proper dimensions.

Australia - English - Department of Health (Therapeutic Goods Administration)

stryker australia pty ltd - 44788 - spinal implant facsimile - manual surgical instruments intended for use in confirming adequate disc space preparation for interbody spinal fusion

Australia - English - Department of Health (Therapeutic Goods Administration)

medacta australia pty ltd - 44788 - spinal implant facsimile - a trial spinal prosthesis used to validate the proper size of the permanent implant required by the patient.

Bangladesh - English - DGDA (Directorate General of Drug Administration)

pharmacare laboratories (unani) - qurs muhazzil - capsule

Australia - English - Department of Health (Therapeutic Goods Administration)

national surgical pty ltd -

European Union - English - EMA (European Medicines Agency)

medice arzneimittel pütter gmbh co. kg - epoetin alfa - anemia; kidney failure, chronic; cancer - antianemic preparations - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy).abseamed can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to patients with moderate anaemia (haemoglobin (hb) 10-13 g/dl [6.2-8.1 mmol/l], no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).abseamed can be used to reduce exposure to allogeneic blood transfusions in adult non iron deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. use should be restricted to patients with moderate anaemia (e.g. hb 10-13 g/dl) who do not have an autologous predonation programme available and with an expected blood loss of 900 to 1800 ml.

European Union - English - EMA (European Medicines Agency)

ratiopharm gmbh - leflunomide - arthritis, rheumatoid - immunosuppressants - leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (dmard);active psoriatic arthritis.recent or concurrent treatment with hepatotoxic or haematotoxic dmards (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.moreover, switching from leflunomide to another dmard without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.